EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers

Xiaoling Shang, Xudong Geng, Zixu Wang, Shumin Yuan, Shanshan Ding, Ni Liu, Xinchun Ma, Xuan Sun, Huimin Wang, Ying Sun, Xun Qu, Guangwen Ren und 3 weitere

Advanced Science · 2026-01 · 13 (1)

DOI: 10.1002/advs.202513182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 27.10.2025. Verfasst von Xiaoling Shang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong, 250012, China. Hauptthemen laut MEDLINE: Dendritic Cells, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, 5'-Nucleotidase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Natural Science Foundation, "20 New Higher Education Initiatives" Research Leader Studio Project of Jinan Science & Technology Bureau, Shandong Provincial Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EGFR mutations remain a major challenge in immunotherapy for non‐small cell lung cancer (NSCLC), with poor responses to immune checkpoint inhibitors driven by mechanisms associated with EGFR mutation‐mediated tumor microenvironment (TME) modulation. This study reveals that EGFR mutations prominently impaired dendritic cell (DC) maturation, disrupting their capacity to effectively prime CD8 + T cells and thereby compromising anti‐tumor immune responses. By application of clinical specimen analyses, multi‐omics approaches, and in vivo mouse models, this work demonstrates that EGFR mutations elicited adenosine production through the ERK/c‐Jun signaling axis in tumor cells, establishing an immunosuppressive TME that impeded maturation and antigen presentation of DCs, and in turn weakened CD8 + T cell activation. To overcome the EGFR mutation‐induced immunosuppression, this work next develops F127 ZIF‐8 AB680 , a pH‐responsive and tumor‐selective nanodrug specifically designed to target the CD73‐adenosine pathway within the acidic TME. This nanodrug significantly improves the therapeutic efficacy of PD‐1 blockade, leading to robust tumor growth inhibition and prolonged survival of mice in EGFR‐mutant NSCLC models. Leveraging the advanced nanotechnology, this newly designed pH‐sensitive nanocarrier introduces a precise CD73/adenosine inhibition within the acidic TME that reprograms the immune landscape in EGFR‐mutant NSCLC, which represents a promising therapeutic strategy to overcome immunotherapy resistance in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsLung NeoplasmsCarcinoma, Non-Small-Cell Lung5'-NucleotidaseAnimalsMiceErbB ReceptorsHumansTumor MicroenvironmentHydrogen-Ion ConcentrationMutationImmunotherapyCell Line, TumorNanoparticlesGPI-Linked Proteins

Stichwörter der Autor:innen

EGFR mutationsF127ZIF‐8AB680adenosinedendritic cellsimmune checkpoint inhibitorsnon‐small cell lung cancer

Substanzen

ErbB Receptors5'-NucleotidaseEGFR protein, humanNT5E protein, humanGPI-Linked Proteins

Autor:innen und Institutionen

  • Department of Medical Oncology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong, 250012, China.
  • Institute of Advanced Interdisciplinary Science, School of Physics, Shandong University, Jinan, Shandong, 250100, China.
  • Department of Clinical Laboratory, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
  • Department of Oncology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, 264100, China.
  • Laboratory of Basic Medical Sciences, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong, 250012, China.
  • The Jackson Laboratory, Bar Harbor, Maine, 04609, USA.

ORCID-Profile: Yanguo Liu

Förderung

  • Shandong Provincial Natural Science Foundation
  • "20 New Higher Education Initiatives" Research Leader Studio Project of Jinan Science & Technology Bureau
  • Shandong Provincial Medical Association
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Shang, X., Geng, X., Wang, Z., Yuan, S., Ding, S., Liu, N., Ma, X., Sun, X., Wang, H., Sun, Y., Qu, X., Ren, G., Li, Y. Q., Wang, X., & Liu, Y. (2026). Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers. Advanced Science, 13(1). https://doi.org/10.1002/advs.202513182

Vancouver

Shang X, Geng X, Wang Z, Yuan S, Ding S, Liu N, et al. Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers. Advanced Science. 2026;13(1). doi:10.1002/advs.202513182

BibTeX
@article{Shang2026,
  author = {Shang, Xiaoling and Geng, Xudong and Wang, Zixu and Yuan, Shumin and Ding, Shanshan and Liu, Ni and Ma, Xinchun and Sun, Xuan and Wang, Huimin and Sun, Ying and Qu, Xun and Ren, Guangwen and Li, Yong Qiang and Wang, Xiuwen and Liu, Yanguo},
  title = {Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {1},
  doi = {10.1002/advs.202513182}
}
Kostenlos starten →